10:52 AM EST - Appili Therapeutics Inc. : Has completed enrollment in its global Phase 3 PRESECO (PREventing SEvere COVID-19) trial evaluating oral Avigan®/Reeqonus™ (favipiravir) as a potential COVID-19 treatment. Appili expects to report top-line data from this trial in approximately 60 days. Appili Therapeutics Inc.
shares T.APLI are trading down $0.01 at $0.95.
